Toronto Dominion Bank Invests $1.38 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Toronto Dominion Bank purchased a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 31,306 shares of the company’s stock, valued at approximately $1,384,000.

Other large investors also recently modified their holdings of the company. Heritage Wealth Management LLC purchased a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter worth approximately $25,000. Ronald Blue Trust Inc. purchased a new position in Ionis Pharmaceuticals in the 2nd quarter valued at approximately $25,000. Wipfli Financial Advisors LLC purchased a new position in Ionis Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Quantbot Technologies LP purchased a new position in Ionis Pharmaceuticals in the 2nd quarter valued at approximately $44,000. Finally, Captrust Financial Advisors grew its stake in Ionis Pharmaceuticals by 21.1% in the 2nd quarter. Captrust Financial Advisors now owns 1,429 shares of the company’s stock valued at $53,000 after buying an additional 249 shares in the last quarter. Hedge funds and other institutional investors own 87.32% of the company’s stock.

Get Ionis Pharmaceuticals alerts:

Ionis Pharmaceuticals Stock Performance

NASDAQ IONS opened at $39.21 on Wednesday. Ionis Pharmaceuticals, Inc. has a 52-week low of $29.68 and a 52-week high of $48.82. The company has a debt-to-equity ratio of 2.10, a quick ratio of 7.52 and a current ratio of 7.59. The company has a market capitalization of $5.57 billion, a P/E ratio of -326.75 and a beta of 0.55. The company has a fifty day moving average of $39.04 and a 200-day moving average of $42.08.

Analyst Ratings Changes

A number of research firms recently weighed in on IONS. Barclays lifted their price objective on shares of Ionis Pharmaceuticals to $44.00 in a research note on Tuesday, November 15th. Piper Sandler lifted their price objective on shares of Ionis Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Thursday, January 19th. Morgan Stanley lowered shares of Ionis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $56.00 to $40.00 in a research note on Wednesday, December 21st. Citigroup boosted their price target on shares of Ionis Pharmaceuticals from $28.00 to $31.00 and gave the company a “sell” rating in a research report on Thursday, November 10th. Finally, SVB Leerink boosted their price target on shares of Ionis Pharmaceuticals from $33.00 to $34.00 and gave the company a “market perform” rating in a research report on Friday, February 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $45.88.

Insider Transactions at Ionis Pharmaceuticals

In other news, CEO Brett P. Monia sold 25,066 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $39.49, for a total transaction of $989,856.34. Following the completion of the sale, the chief executive officer now directly owns 120,863 shares of the company’s stock, valued at approximately $4,772,879.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Patrick R. O’neil sold 4,500 shares of Ionis Pharmaceuticals stock in a transaction on Monday, January 30th. The shares were sold at an average price of $39.42, for a total transaction of $177,390.00. Following the completion of the sale, the executive vice president now directly owns 44,179 shares of the company’s stock, valued at approximately $1,741,536.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brett P. Monia sold 25,066 shares of the business’s stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $39.49, for a total transaction of $989,856.34. Following the completion of the sale, the chief executive officer now directly owns 120,863 shares of the company’s stock, valued at $4,772,879.87. The disclosure for this sale can be found here. In the last ninety days, insiders sold 74,022 shares of company stock valued at $2,961,208. Insiders own 2.36% of the company’s stock.

Ionis Pharmaceuticals Profile

(Get Rating)

Ionis Pharmaceuticals, Inc engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases.

Read More

• Get a free copy of the StockNews.com research report on Ionis Pharmaceuticals (IONS)
• LCI Industries Diversification Strategy Pays Off
• Is It Time To Buy The Dip In The Coca-Cola Company 
• Ex-Dividend Date vs. Record Date: What’s the Difference?
• How Does the Consumer Price Index Affect the Stock Market?
• Are Denny’s Corporation Investors Due For A Grand Slam?

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.